PMID- 30657656
OWN - NLM
STAT- MEDLINE
DCOM- 20190502
LR  - 20190502
IS  - 0370-0747 (Print)
IS  - 0370-0747 (Linking)
VI  - 48
IP  - 1
DP  - 2018 Jan-Jun
TI  - Formulation and characterization of oral rapid disintegrating tablets of 
      levocetirizine.
PG  - 31-40
LID - 10.17219/pim/99951 [doi]
AB  - BACKGROUND: Levocetirizine, active R (-) enantiomer of cetirizine, is an orally 
      active and selective H1 receptor antagonist used medically as an anti-allergic. 
      Allergic rhinitis is a symptomatic disorder of the nose induced by inflammation 
      mediated by immunoglobulin E (IgE) in the membrane lining the nose after allergen 
      exposure. OBJECTIVES: The purpose of the present study was to prepare rapidly 
      disintegrating tablets of levocetirizine after its complexation with 
      beta-cyclodextrin (beta-CD). MATERIAL AND METHODS: Levocetirizine-beta-CD complex tablets 
      were prepared by direct compression technique using 3 synthetic 
      superdisintegrants in different proportions. Development of the formulation in 
      the present study was mainly based on the concentration of superdisintegrants and 
      the properties of the drug. Nine batches of tablets were formulated and evaluated 
      for various parameters: drug content, weight variation, water absorption ratio, 
      wetting time, in vitro disintegration, hardness, friability, thickness 
      uniformity, and in vitro dissolution. RESULTS: A Fourier-transform infrared 
      spectroscopy (FTIR) study showed that there were no significant interactions 
      between the drug and the excipients. The prepared tablets were good in appearance 
      and showed acceptable results for hardness and friability. The in vitro 
      disintegrating time of the formulated tablet batches was found to be 15-35 s 
      percentage and the drug content of tablets in all formulations was found to be 
      between 90-102%, which complied with the limits established in the United States 
      Pharmacopeia. CONCLUSIONS: Complexation of levocetirizine with beta-CD significantly 
      improves the solubility of the drug. The disintegration time of the tablets was 
      decreased with an increase in superdisintegrant amount. The tablets (batch CPX5) 
      had a minimum disintegration time of 20 s and 99.99% of the drug was released 
      within 10 min.
FAU - Samvedna, Samvedn
AU  - Samvedna S
AD  - Laureate Institute of Pharmacy, Jawalamukhi, India.
FAU - Jindal, Shammy
AU  - Jindal S
AD  - Laureate Institute of Pharmacy, Jawalamukhi, India.
FAU - Mishra, Gaurav
AU  - Mishra G
AD  - Drug Delivery and Nanotechnology Laboratory, Bhagyoday Teerth Pharmacy College, 
      Sagar, India.
FAU - Madan, Jyotsana R
AU  - Madan JR
AD  - Department of Pharmaceutics, Smt. Kashibai Navale College of Pharmacy, Savitribai 
      Phule Pune University, India.
FAU - Gupta, Gaurav
AU  - Gupta G
AD  - School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, India.
FAU - Awasthi, Rajendra
AU  - Awasthi R
AD  - Amity Institute of Pharmacy, Amity University, Noida, India.
FAU - Pinto, Terezinha De Jesus Andreoli
AU  - Pinto TJA
AD  - Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of Sao 
      Paulo, Brazil.
FAU - Dua, Kamal
AU  - Dua K
AD  - Discipline of Pharmacy, Graduate School of Health, University of Technology, 
      Sydney, Australia.
FAU - Kulkarni, Giriraj T
AU  - Kulkarni GT
AD  - Amity Institute of Pharmacy, Amity University, Noida, India.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Polim Med
JT  - Polimery w medycynie
JID - 7509477
RN  - 0 (Tablets)
RN  - 6U5EA9RT2O (levocetirizine)
RN  - YO7261ME24 (Cetirizine)
SB  - IM
MH  - Administration, Oral
MH  - *Cetirizine/chemistry
MH  - *Chemistry, Pharmaceutical
MH  - Hardness
MH  - Solubility
MH  - Tablets
OTO - NOTNLM
OT  - direct compression
OT  - rapidly disintegrating tablets
OT  - superdisintegrants
OT  - beta-cyclodextrin complex
EDAT- 2019/01/19 06:00
MHDA- 2019/05/03 06:00
CRDT- 2019/01/19 06:00
PHST- 2019/01/19 06:00 [entrez]
PHST- 2019/01/19 06:00 [pubmed]
PHST- 2019/05/03 06:00 [medline]
AID - 10.17219/pim/99951 [doi]
PST - ppublish
SO  - Polim Med. 2018 Jan-Jun;48(1):31-40. doi: 10.17219/pim/99951.